NEW YORK (GenomeWeb News) – Myriad Genetics has sued a fifth firm alleging infringement of its patents covering BRCA1 and BRCA2 gene testing.

In a lawsuit filed on Monday in US District Court for the District of Utah, Central Division, Myriad claims that Invitae infringes 11 patents held by Myriad, along with other assignees – the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research Development Limited Partnership (Hospital for Sick Children in Toronto), and Endorecherche.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.